Winship's Protocol Review and Monitoring System (PRMS) requires the review of all proposed cancer clinical trials for scientific quality and merit. The PRMS also calls for the prioritization, monitoring, and termination of protocols based on scientific progress and patient accrual. The Winship Clinical and Translational Review Committee (CTRC) is responsible for these functions. The CTRCs purposes are: 1. To review new proposals for clinical research to ensure that they are scientifically meritorious, that they address significant scientific issues, and that there are sufficient patient and institutional resources to conduct the study as proposed. 2. To prioritize among clinical research proposals within cancer disease sites in order to best fulfill the strategic objectives of the Winship Cancer Institute and of its four research programs. 3. To review the scientific progress of existing clinical research protocols and to terminate protocols in which accrual rates are inconsistent with meeting the stated scientific objective or in which new scientific data renders the trial as having greater safety or efficacy issues or as less scientifically important. 4. To monitor studies for the accuracy and validity of the clinical and laboratory data obtained during the conduct of the clinical study. PRMS is now clearly separated from the Winship Clinical Trials Office (CTO) and the Data Safety and Monitoring Plan (DSMP). In addition, the CTRC has tightened the criteria for new study proposals to achieve scientific review. The changes in criteria include: 1) strict rules regarding the ability of new studies to meet accrual targets, with special attention to any potential eligibility conflict with any ongoing clinical trials, and 2) a requirement that new study proposals address scientific questions relevant to the Winship Cancer Institute's overall scientific goals. The CTRC, under the direction of Thomas Olson, M.D. and Taofeek Owonikoko, Ph.D., M.D expanded to include 24 members and meets on a twice monthly basis to review all proposed cancer clinical trials.

Public Health Relevance

The Protocol Review and Monitoring System (PRMS) ensures that all cancer-related clinical research studies Involving human subjects that are conducted at the Winship Cancer Institute are scientifically evaluated and prioritized.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Havel, L S; Kline, E R; Salgueiro, A M et al. (2015) Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene 34:1979-90
Forghani, Parvin; Khorramizadeh, Mohammad R; Waller, Edmund K (2014) Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. Cancer Med 3:215-24
Smith, Alicia K; Conneely, Karen N; Pace, Thaddeus W W et al. (2014) Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy. Brain Behav Immun 38:227-36
Ha, Shin-Woo; Weitzmann, M Neale; Beck Jr, George R (2014) Bioactive silica nanoparticles promote osteoblast differentiation through stimulation of autophagy and direct association with LC3 and p62. ACS Nano 8:5898-910
Nooka, Ajay K; Johnson, Heather R; Kaufman, Jonathan L et al. (2014) Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20:852-7
Capaldo, Christopher T; Farkas, Attila E; Hilgarth, Roland S et al. (2014) Proinflammatory cytokine-induced tight junction remodeling through dynamic self-assembly of claudins. Mol Biol Cell 25:2710-9
Sullivan, Harold C; Oprea-Ilies, Gabriela; Adams, Amy L et al. (2014) Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. Appl Immunohistochem Mol Morphol 22:17-23
Brodie, Seth A; Li, Ge; El-Kommos, Adam et al. (2014) Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer Prev Res (Phila) 7:351-61
Wang, Hongyan; Wang, Ya (2014) Heavier ions with a different linear energy transfer spectrum kill more cells due to similar interference with the Ku-dependent DNA repair pathway. Radiat Res 182:458-61
Jurchenko, Carol; Chang, Yuan; Narui, Yoshie et al. (2014) Integrin-generated forces lead to streptavidin-biotin unbinding in cellular adhesions. Biophys J 106:1436-46

Showing the most recent 10 out of 49 publications